{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:59:33Z","timestamp":1791849573240,"version":"4.3.4"},"reference-count":60,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder with diverse clinical presentations, often posing significant diagnostic challenges. Methods: We report the case of a 20-year-old woman who first presented with fever of unknown origin (FUO) at the age of 14, followed by the development of abdominal lymphadenopathy. We conducted a comprehensive review of her clinical course, diagnostic workup, treatment response, and outcomes. Additionally, we performed a literature review of CD focusing on pathophysiology, classification, diagnostic approaches, and treatment strategies. Results: Extensive investigations performed in the meantime excluded infectious and autoimmune causes. Histopathological analysis of the excised lymph nodes ruled out malignancy and confirmed idiopathic multicentric Castleman disease. Treatment with tocilizumab, an IL-6 receptor antagonist, resulted in rapid resolution of clinical symptoms, normalization of inflammatory markers, and sustained remission. With the final diagnosis established and treatment initiated, she was transitioned at the age of 18 from a pediatric immunology to an adult clinical immunology center. Conclusions: The presented case highlights the importance of considering iMCD in the differential diagnosis of FUO, especially in adolescents, and the efficacy of targeted therapies in managing this challenging disease. A multidisciplinary approach involving clinical, laboratory, imaging, and histopathological evaluation is essential for accurate diagnosis. IL-6 pathway inhibition represents an effective targeted therapy for iMCD, capable of inducing sustained remission in this challenging disease.<\/jats:p>","DOI":"10.3390\/jcm14082799","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T06:23:56Z","timestamp":1744957436000},"page":"2799","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Castleman Disease\u2014Still More Questions than Answers: A Case Report and Review of the Literature"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6162-9916","authenticated-orcid":false,"given":"Mariusz","family":"Sikora","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Pneumonology, Allergology, Clinical Immunology and Rare Diseases, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-9713","authenticated-orcid":false,"given":"Nel","family":"D\u0105browska-Leonik","sequence":"additional","affiliation":[{"name":"Department of Immunology, Children\u2019s Memorial Health Institute, 04-730 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-4989","authenticated-orcid":false,"given":"Piotr","family":"Buda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nutrition and Metabolic Disorders, Children\u2019s Memorial Health Institute, 04-730 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Wolska-Ku\u015bnierz","sequence":"additional","affiliation":[{"name":"Department of Immunology, Children\u2019s Memorial Health Institute, 04-730 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3505-1858","authenticated-orcid":false,"given":"Karina","family":"Jahnz-R\u00f3\u017cyk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pneumonology, Allergology, Clinical Immunology and Rare Diseases, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2071-3297","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Pac","sequence":"additional","affiliation":[{"name":"Department of Immunology, Children\u2019s Memorial Health Institute, 04-730 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-4453","authenticated-orcid":false,"given":"Ewa","family":"Wi\u0119sik-Szewczyk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pneumonology, Allergology, Clinical Immunology and Rare Diseases, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"ref_1","first-page":"1001","article-title":"Case records of the Massachusetts General Hospital: Case No. 40231","volume":"250","author":"Castleman","year":"1954","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3960\/jslrt.21036","article-title":"Historical and pathological overview of Castleman disease","volume":"62","author":"Nishimura","year":"2022","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bjh.18214","article-title":"The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry","volume":"198","author":"Fajgenbaum","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1182\/bloodadvances.2023010745","article-title":"Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes","volume":"7","author":"Pierson","year":"2023","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.12717","article-title":"Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: Results from two US treatment centres","volume":"165","author":"Robinson","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e924783","DOI":"10.12659\/MSM.924783","article-title":"Analysis of Clinical Characteristics, Pathological Changes and Changes of Interleukin-6 (IL-6) and C-Reactive Protein (CRP) in Children with Castleman\u2019s Disease","volume":"26","author":"Hu","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s004310051166","article-title":"Paediatric Castleman disease: Report of seven cases and review of the literature","volume":"158","author":"Parez","year":"1999","journal-title":"Eur. J. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Trapani, S., Fiordelisi, A., Stinco, M., and Resti, M. (2023). Update on Fever of Unknown Origin in Children: Focus on Etiologies and Clinical Approach. Children, 11.","DOI":"10.3390\/children11010020"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.idc.2007.09.002","article-title":"Fever of unknown origin: Clinical overview of classic and current concepts","volume":"21","author":"Cunha","year":"2007","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMra2111003","article-title":"Fever of Unknown Origin","volume":"386","author":"Haidar","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"ofac151","DOI":"10.1093\/ofid\/ofac151","article-title":"Geographic Variation of Infectious Disease Diagnoses Among Patients With Fever of Unknown Origin: A Systematic Review and Meta-analysis","volume":"9","author":"Wright","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_15","first-page":"4076159","article-title":"Q Fever Presented as a Large Retroperitoneal Pseudotumoral Mass","volume":"2017","author":"Nowroozizadeh","year":"2017","journal-title":"Case Rep. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7861\/clinmedicine.15-3-292","article-title":"Malignant causes of fever of unknown origin","volume":"15","author":"Foggo","year":"2015","journal-title":"Clin. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/cid\/ciac040","article-title":"Fever of Unknown Origin and Incidence of Cancer","volume":"75","author":"Sogaard","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5114\/reum.2019.91298","article-title":"Monogenic autoinflammatory diseases in adults\u2014A challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment","volume":"57","author":"Milchert","year":"2019","journal-title":"Reumatologia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Molacek, J., Treska, V., Skalicky, T., Vodicka, J., Ferda, J., Ferdova, E., Baxa, J., Mach, C., Jungova, A., and Michal, M. (2023). Unicentric form of Castleman s disease, pitfalls of diagnosis and surgical treatment. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1057683"},{"key":"ref_21","first-page":"199","article-title":"Case report Castleman\u2019s disease imitating pancreatic tumour\u2014Diagnostic difficulties","volume":"2","author":"Kaniewska","year":"2007","journal-title":"Gastroenterol. Rev.\/Prz. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3718305","DOI":"10.1155\/2020\/3718305","article-title":"Clinical Analysis of Castleman\u2019s Disease of the Lacrimal Gland","volume":"2020","author":"Li","year":"2020","journal-title":"J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00256-014-1945-z","article-title":"Extranodal Castleman disease of the extremities: A case report and review of the literature","volume":"43","author":"Eward","year":"2014","journal-title":"Skelet. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109688","DOI":"10.1016\/j.ijscr.2024.109688","article-title":"Unicentric Castleman disease: A case report of an atypical presentation and successful management","volume":"118","author":"Muhammad","year":"2024","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_25","first-page":"500","article-title":"Fever of unknown origin as initial manifestation of Castleman\u2019s disease: Apropos of 2 cases","volume":"13","year":"1996","journal-title":"An. Med. Interna"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MAJ.0b013e31818803f4","article-title":"Castleman\u2019s disease presenting as fever of unknown origin: Diagnostic value of fluorodeoxyglucose-positron emission tomography\/computed tomography","volume":"337","author":"Roca","year":"2009","journal-title":"Am. J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/imj.14404","article-title":"Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: A 6-year retrospective study","volume":"50","author":"Nishimura","year":"2020","journal-title":"Intern. Med. J."},{"key":"ref_28","first-page":"2196","article-title":"Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease","volume":"109","author":"Bustamante","year":"2024","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e29261","DOI":"10.1002\/pbc.29261","article-title":"Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: A pediatric case series","volume":"68","author":"Lust","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Castleman disease: 273 patients studied over 20 years","volume":"180","author":"Oksenhendler","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/rheumatology\/keac481","article-title":"Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: Practical guidance for diagnosis","volume":"62","year":"2023","journal-title":"Rheumatology"},{"key":"ref_32","first-page":"83","article-title":"Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology","volume":"66","author":"Soudet","year":"2018","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.crad.2022.01.045","article-title":"Radiology of Castleman disease: The pivotal role of imaging in diagnosis, staging, and response assessment of this rare entity","volume":"77","author":"Din","year":"2022","journal-title":"Clin. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e220210","DOI":"10.1148\/rg.220210","article-title":"Imaging of Castleman Disease","volume":"43","author":"Pitot","year":"2023","journal-title":"Radiographics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MNM.0000000000001404","article-title":"18F-FDG PET\/CT imaging features of patients with multicentric Castleman disease","volume":"42","author":"Jiang","year":"2021","journal-title":"Nucl. Med. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11604-022-01318-6","article-title":"(18)F-FDG PET\/CT and contrast-enhanced CT in the diagnosis of Castleman disease","volume":"41","author":"He","year":"2023","journal-title":"Jpn. J. Radiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/ajh.25992","article-title":"Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease","volume":"95","author":"Fajgenbaum","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.hoc.2017.09.004","article-title":"Pathology of Castleman Disease","volume":"32","author":"Wu","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.12998\/wjcc.v10.i29.10794","article-title":"Glucocorticoids combined with tofacitinib in the treatment of Castleman\u2019s disease: A case report","volume":"10","author":"Liu","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jid.2023.07.031","article-title":"Whole-Exome Sequencing Reveals the Genomic Profile and IL6ST Variants as a Prognostic Biomarker of Paraneoplastic Pemphigus-Associated Unicentric Castleman Disease","volume":"144","author":"Wang","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/bjh.16330","article-title":"Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease","volume":"188","author":"You","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","article-title":"Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas","volume":"2","author":"Nagy","year":"2018","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Butzmann, A., Kumar, J., Sridhar, K., Gollapudi, S., and Ohgami, R.S. (2021). A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease. Biology, 10.","DOI":"10.3390\/biology10040251"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/15476286.2020.1795584","article-title":"The immunomodulatory role of Regnase family RNA-binding proteins","volume":"17","author":"Fischer","year":"2020","journal-title":"RNA Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1042\/BJ20130019","article-title":"Zc3h12c inhibits vascular inflammation by repressing NF-kappaB activation and pro-inflammatory gene expression in endothelial cells","volume":"451","author":"Liu","year":"2013","journal-title":"Biochem. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1038\/s41467-021-24352-w","article-title":"The RNase MCPIP3 promotes skin inflammation by orchestrating myeloid cytokine response","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imcb.12521","article-title":"ZC3H12C expression in dendritic cells is necessary to prevent lymphadenopathy of skin-draining lymph nodes","volume":"100","author":"Clayer","year":"2022","journal-title":"Immunol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hoc.2017.09.002","article-title":"Castleman Disease Pathogenesis","volume":"32","author":"Fajgenbaum","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5603\/AHP.2021.0005","article-title":"Idiopathic multicentric Castleman disease: Pathogenesis, clinical presentation and recommendations for treatment based on the Castleman Disease Collaborative Network (CDCN)","volume":"52","author":"Ostrowska","year":"2021","journal-title":"Acta Haematol. Pol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"Voorhees","year":"2018","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ejh.13823","article-title":"Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review","volume":"109","author":"Rehman","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5152\/TurkThoracJ.2018.18066","article-title":"Biologic Agents in the Treatment of Multicentric Castleman Disease","volume":"19","author":"Kapriniotis","year":"2018","journal-title":"Turk. Thorac. J."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Rossini, B., Cecchi, N., Clemente, F., De Paolis, M.R., Hohaus, S., Innao, V., Lucignano, M., Massaiu, R., Palumbo, G., and Rigolin, G.M. (2024). Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: A collection of clinical experiences. Drugs Context, 13.","DOI":"10.7573\/dic.2023-4-5"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"20406207221082552","DOI":"10.1177\/20406207221082552","article-title":"Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: A case report","volume":"13","author":"Lang","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/1535-7163.MCT-10-0156","article-title":"Successful treatment of Castleman\u2019s disease with interleukin-1 receptor antagonist (Anakinra)","volume":"9","author":"Janku","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MPH.0b013e31818ab31f","article-title":"IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: Case report","volume":"30","author":"Galeotti","year":"2008","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13023-020-1345-5","article-title":"The French paediatric cohort of Castleman disease: A retrospective report of 23 patients","volume":"15","author":"Borocco","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.19171","article-title":"The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features","volume":"204","author":"Pelliccia","year":"2024","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2799\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:17:14Z","timestamp":1760030234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082799"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082799","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}